Informations générales (source: ClinicalTrials.gov)
COVID-19 and Rare Skin Diseases. European Observational Study (Data Research) During an Epidemic
Observational [Patient Registry]
Imagine Institute (Voir sur ClinicalTrials)
juin 2020
décembre 2022
29 juin 2024
This is a European observational cohort study (data research) involving multiple centres
to look at the potential impact of COVID infection on patients with rare skin diseases
examining factors such as comorbidity, protection factors, and clinical and/or
therapeutic factors. The data collected may provide additional information on the
situation of patients and, on a wider basis, provide useful data applicable to the
general population.
Etablissements
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| AP-HP - Hôpital Necker-Enfants Malades | Anna Garofano, PhD | Contact (sur clinicalTrials) | |||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| Hôpital Charles Nicolle (CHU de Rouen) - 76031 - Rouen - Seine-Maritime - France | Marion Castel, MD | Contact (sur clinicalTrials) | |||
| Hôpital de Brabois (CHU de Nancy) - 54511 - Vandœuvre-lès-Nancy - Meurthe-et-Moselle - France | Julie Boulanger, Resident | Contact (sur clinicalTrials) | |||
| Hôpital de Clocheville (CHRU de Tours) - 37000 - Tours - Indre-et-Loire - France | Emiliène Edée, CRA | Contact (sur clinicalTrials) | |||
| Hôpital de l'Archet 2 (CHU de Nice) - 06202 - Nice - Alpes-Maritimes - France | Jocelyn Rapp, CRA | Contact (sur clinicalTrials) | |||
| Hôpital Saint Louis (AP-HP) - 75010 - Paris - Ile-de-France - France | Hafsoiti Hassan Djohar, CRA | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Patient with a rare skin disease,
- Patient of any age (paediatric or adult),
- Patient with suspected COVID-19 infection (remote consultation, face-to-face
consultation, general practitioner, hospital physician),
- Patient in contact with a subject infected with the COVID-19 virus,
- Asymptomatic patient for COVID-19 viral infection but with a positive serology,
- Study information given to the patient and/or to their legal representative,
- Patient who has been informed and has agreed to this data collection process.
- Patient with a rare skin disease,
- Patient of any age (paediatric or adult),
- Patient with suspected COVID-19 infection (remote consultation, face-to-face
consultation, general practitioner, hospital physician),
- Patient in contact with a subject infected with the COVID-19 virus,
- Asymptomatic patient for COVID-19 viral infection but with a positive serology,
- Study information given to the patient and/or to their legal representative,
- Patient who has been informed and has agreed to this data collection process.
- Patients not suffering from a rare skin disease,
- Patient and/or their legal representative who object to their participation in the
study at the presentation of the information leaflet,
- Adult patient unable to understand the implications and constraints of the study,
- Protected adult subject to guardianship or safeguarding measures.